Recap: Landos Biopharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Landos Biopharma (NASDAQ:LABP) reported Q4 earnings with an EPS of $-0.99, missing estimates by -9.0% and showing no revenue change from the previous year. The company's past earnings miss led to a 7% drop in share price the following day.
March 21, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Landos Biopharma reported a Q4 EPS of $-0.99, missing estimates by -9.0%, with no revenue change from last year. Previous earnings misses have negatively impacted share price.
Given the reported earnings miss and the historical context of a 7% share price drop following the last earnings miss, it's likely that LABP's share price will face downward pressure in the short term. The consistent underperformance in earnings, as indicated by the miss in estimates, suggests a negative sentiment among investors which could lead to a decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100